Brief: Rubius Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Red Cell Therapeutic, RTX-134
11/03/2019 12:16
March 11 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR FIRST-EVER RED CELL THERAPEUTIC,
RTX-134, FOR TREATMENT OF PHENYLKETONURIA
* RUBIUS THERAPEUTICS INC - COMPANY PLANS TO BEGIN
ENROLLMENT
DURING Q2 OF 2019, WITH INITIAL CLINICAL DATA EXPECTED DURING
SECOND HALF OF 2019.
Source text for Eikon: ID:nGNX9gvVyB
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft